Glaucoma Surgical Microcatheter Market Size, Trends & Growth Opportunity By Product Type, By Procedure Type, By End User, By Reimbursement Environment, By Region and Forecast Till 2030

Report ID : AMR1006226 | Industries : Healthcare | Published On :October 2026 | Page Count : 276

Request Sample
Ask for Customization

Glaucoma Surgical Microcatheter Market Overview & Definition

The global glaucoma surgical microcatheter market covers microcatheters used in canaloplasty and related ab-interno and ab-externo minimally invasive glaucoma surgery (MIGS) procedures, supplied to eye hospitals, surgery centres and ophthalmology clinics worldwide.

A glaucoma surgical microcatheter is a fine surgical device used within the glaucoma procedure categories this report tracks, and this report describes the category strictly as a market segment.

It makes no claim about clinical efficacy, intraocular pressure reduction, complication rates or surgical outcomes for any product, procedure or company described on these pages.

The market is defined by the device rather than by the diagnosis, so it counts the microcatheters supplied for canaloplasty-type procedures and excludes trabecular micro-bypass stents, drainage implants, topical glaucoma pharmaceuticals and laser trabeculoplasty.

Eight segmentation dimensions structure the report, covering product type, procedure type, surgical approach, technology platform, end user, glaucoma type, reimbursement environment and procurement model.

Product type spans four categories, illuminated canaloplasty microcatheters, non-illuminated surgical microcatheters, integrated drug delivery microcatheters and next-generation navigation-enhanced microcatheters.

Procedure type spans four categories, canaloplasty, ab-interno canaloplasty, combined cataract and canaloplasty procedures and hybrid MIGS procedures, while surgical approach separates the ab-interno approach from the ab-externo approach.

Technology platform distinguishes traditional canaloplasty systems, MIGS-oriented canaloplasty platforms and image-guided systems.

End user covers ophthalmology hospitals, specialty eye hospitals, ambulatory surgery centres, academic ophthalmology centres and private ophthalmology clinics, and glaucoma type covers primary open-angle, normal-tension, secondary open-angle and pseudoexfoliative glaucoma.

Reimbursement environment separates public, mixed and private pay markets, and procurement model separates direct hospital procurement, group purchasing organisations, distributor-led procurement and integrated surgical package procurement.

The most useful commercial observation about this market is that a microcatheter purchase is a surgeon-led decision long before it becomes a procurement decision.

The sales cycle described in the report runs through a clinical evaluation phase and a surgeon validation phase before procurement review and contract award, which means a device is usually chosen by the people who will use it well before any contract is negotiated.

That ordering shapes the market in three ways: clinical evidence and surgeon familiarity weigh more heavily than list price, adoption spreads through surgeon training and peer networks rather than through catalogues, and reimbursement decides how quickly a hospital can act on a surgeon's preference.

Twelve companies are covered, ranging from canaloplasty and MIGS specialists to diversified global ophthalmology companies, and the geographic scope spans North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa, with named states and cities in four countries.

The sections that follow set out size and growth, the drivers, restraints and opportunities, the segmentation, the regional picture and the supplier landscape.

Market Size & Growth Forecast (2026 to 2030)

The global glaucoma surgical microcatheter market is estimated at approximately USD 150 Million in 2025 and is projected to reach approximately USD 215 Million by 2030, expanding at a compound annual growth rate of roughly 7.5 percent.

The estimate covers microcatheters used in canaloplasty-type glaucoma procedures and excludes trabecular micro-bypass stents, drainage implants, topical glaucoma pharmaceuticals and laser trabeculoplasty.

No published market estimate exists for this exact device category, so the figure is a disclosed top-down estimate built from the wider glaucoma surgery device market, and the Research Methodology section sets out every step and every assumption behind it.

The estimate should be read as an indicative order of magnitude rather than a precise measurement, since two of its inputs are analyst assumptions rather than sourced figures.

Illuminated canaloplasty microcatheters account for the largest product type category, reflecting their established position in canaloplasty, while next-generation navigation-enhanced microcatheters form the fastest-growing product type category from a small base.

Combined cataract and canaloplasty procedures account for the largest procedure type category, because cataract surgeons performing MIGS bring the largest volume of eligible eyes, and hybrid MIGS procedures form the fastest-growing procedure type category.

The ab-interno approach accounts for the largest surgical approach category, and traditional canaloplasty systems remain the largest technology platform category while MIGS-oriented canaloplasty platforms form the fastest-growing platform category.

Ophthalmology hospitals account for the largest end user category, and ambulatory surgery centres form the fastest-growing end user category as procedures move toward outpatient settings.

Primary open-angle glaucoma is the largest glaucoma type category in the segmentation, and public and mixed reimbursement markets together account for the largest reimbursement environment category.

North America accounts for the largest regional concentration in this report, while Asia-Pacific forms the fastest-growing region, the two being distinct because the largest region reflects an established base and the fastest-growing region reflects expanding surgical capacity.

The forecast assumes glaucoma surgical volumes continue to grow broadly in line with recent trends and that reimbursement for minimally invasive glaucoma procedures remains broadly stable, and a material change in coverage in a large market would move the trajectory.

MetricValue
Market Size (2025)Approximately USD 150 Million
Forecast Size (2030)Approximately USD 215 Million
CAGR (2025-2030)Approximately 7.5%
Base Year2025
Forecast Period2026-2030 (5-year)
Sizing BasisDisclosed top-down estimate from the wider glaucoma surgery device market, with two analyst assumptions (see Research Methodology)
Scope NoteMicrocatheters used in canaloplasty-type glaucoma procedures only; excludes trabecular micro-bypass stents, drainage implants, topical pharmaceuticals and laser trabeculoplasty
Largest Product CategoryIlluminated canaloplasty microcatheters
Fastest-Growing Product CategoryNext-generation navigation-enhanced microcatheters
Largest Procedure CategoryCombined cataract and canaloplasty procedures
Fastest-Growing Procedure CategoryHybrid MIGS procedures
Largest End User CategoryOphthalmology hospitals
Fastest-Growing End User CategoryAmbulatory surgery centres
Largest Regional ConcentrationNorth America
Fastest-Growing RegionAsia-Pacific

 

Market Drivers

An ageing population is the broadest driver, since it enlarges the pool of people who are candidates for glaucoma surgery, and the report tracks four glaucoma type categories across that pool.

Surgeon preference for combining cataract surgery with a glaucoma procedure is a second driver, because the Procedure Type segmentation treats combined cataract and canaloplasty procedures as a distinct and expanding category beside standalone and ab-interno canaloplasty.

The shift toward ab-interno approaches and MIGS-oriented canaloplasty platforms is a third driver, and the Technology Platform segmentation separates these newer platforms from traditional canaloplasty systems and from image-guided systems.

Product innovation widens the addressable procedure base, since integrated drug delivery and navigation-enhanced microcatheters are both named product type categories alongside the conventional illuminated and non-illuminated designs.

Reimbursement support is the fifth driver, and the source names it directly as a buying trigger, with public, mixed and private pay reimbursement environments tracked as separate segments that set the pace of adoption by geography.

Capacity growth at ambulatory surgery centres and specialty eye hospitals is the sixth driver, because both are named end user categories and both broaden the sites of care where canaloplasty procedures are performed.

MARKET SHIFT

The move toward combined cataract and glaucoma procedures changes who the decision maker is, since a cataract surgeon who adds a minimally invasive glaucoma step becomes a purchaser of devices that were once chosen almost entirely by glaucoma specialists.

 

Market Restraints

Long evaluation phases are the first restraint, since the sales cycle runs through clinical evaluation and surgeon validation before procurement review and contract award, and a new microcatheter platform can wait through all four stages.

Reimbursement variability is the second restraint, because the same procedure can sit in a public, mixed or private pay environment depending on the country, and purchasing willingness follows the environment.

Vendor selection criteria are the third restraint for newer entrants, as clinical evidence, regulatory approvals, surgeon experience, product reliability and training support are all named criteria, and each takes time and capital to build.

Competitive intensity is the fourth restraint, with the twelve companies covered ranging from large diversified ophthalmology companies to focused MIGS specialists that compete for the same surgeon attention.

Distributor-led and tender-based procurement is the fifth restraint, because both are named procurement models and both can lengthen the path to revenue in markets where direct manufacturer contracting is not the norm.

Training and surgeon support obligations are the sixth restraint, since training support is itself a named selection criterion and a manufacturer that cannot staff it will struggle to convert interest into repeat use.

PROCUREMENT INSIGHT

Because surgeon validation precedes procurement review, a manufacturer that invests in training and clinical publications before a tender opens is often competing for a decision that has already been narrowed by the clinicians who will use the device.

 

Market Opportunities

The report's competitive mapping identifies considerable untapped opportunity across technology gaps, procedure adoption gaps and emerging market opportunities, which together mark where demand and supply are least well matched.

Emerging ophthalmology markets are a named regional demand cluster, set beside advanced surgical markets and reimbursement-driven markets, and they offer room for suppliers able to pair a device with training.

Clinical evidence gaps favour manufacturers that invest in clinical publications and regulatory approvals ahead of competitors, because evidence is the first criterion buyers name when selecting a vendor.

Hybrid MIGS procedures and combined cataract and canaloplasty procedures broaden the surgical volume a single microcatheter platform can address, which improves the return on surgeon training.

Group purchasing organisations and integrated surgical package procurement can accelerate multi-hospital adoption, since a single agreement can open a whole network once the clinical case has been made at one site.

Named demand clusters in Australia, the United States, Germany and Japan point to specific cities and states where adoption activity concentrates, including Sydney, Melbourne, Brisbane and Perth, California, Texas, Florida and New York, Bavaria, North Rhine-Westphalia and Baden-Wurttemberg, and Tokyo, Osaka and Nagoya.

Product Types, Technology Platforms and Surgical Approaches

Buyers weighing microcatheter product types and platforms start with the surgical approach, ab-interno or ab-externo, since it narrows the four product type categories and the three technology platform categories before any comparison of illumination, drug delivery or navigation features begins.

Procedure Types and Glaucoma Indications

Surgeons mapping demand across canaloplasty procedure types look first at the glaucoma type being treated, because the four glaucoma type categories decide which of the four procedure categories, from standalone canaloplasty to hybrid MIGS procedures, is considered first.

End Users and Reimbursement Environments

Where a procedure is performed matters less to purchasing pace than who pays for it, and the end users and reimbursement environments covered here set five sites of care against three reimbursement environments to show why similar hospitals can adopt at very different speeds.

Procurement Models and Decision Makers

Contract route and buying committee differ more than most buyers expect, and the procurement models and decision makers in this category span direct hospital purchasing, group purchasing organisations, distributors and integrated surgical packages, each shaped by the vendor selection criteria buyers apply.

Glaucoma Surgical Microcatheter Market, By Region

North America accounts for the largest regional concentration in this report, covering the United States and Canada, with the United States analysed through California, Texas, Florida and New York.

Europe is covered through Germany, the United Kingdom, France, Italy, Spain and the Netherlands, and Germany is analysed through Bavaria, North Rhine-Westphalia and Baden-Wurttemberg, where adoption activity is named as a demand cluster.

Asia-Pacific forms the fastest-growing region, covering Australia, Japan, China, South Korea, India and Singapore, with Australia analysed through Sydney, Melbourne, Brisbane and Perth and Japan through Tokyo, Osaka and Nagoya.

Latin America is covered through Brazil and Mexico, and the Middle East and Africa through Saudi Arabia, the United Arab Emirates and South Africa, both of which the report associates with emerging ophthalmology demand rather than with established surgical markets.

Regions differ mainly in reimbursement environment and in how procurement is run, so the same product type can be bought through a public tender in one country and through a private pay agreement in another.

The report's regional clusters reflect this by grouping markets as advanced surgical markets, reimbursement-driven markets and emerging ophthalmology markets, a grouping that cuts across the five regional headings.

REGIONAL OPPORTUNITY

Asia-Pacific combines named city clusters in Australia and Japan with large populations in China, India and South Korea, which gives suppliers a path from a few dense surgical centres toward wider national coverage as capacity expands.

 

Leading Companies

Twelve suppliers are covered, from canaloplasty and MIGS specialists to diversified ophthalmology groups, and the leading glaucoma microcatheter manufacturers are grouped by company type rather than ranked, with Nova Eye Medical named first among the companies covered and described on the same factual basis as every other company.

Beyond This Page

The full report extends well past the segmentation summarised here and into the commercial detail that shapes how glaucoma surgical microcatheter supply is actually won.

Buyer intelligence maps glaucoma specialists, cataract surgeons performing MIGS, ophthalmology hospital networks and academic eye centres in full, including a dedicated strategic relevance assessment for Nova Eye Medical.

Decision-maker mapping covers vendor selection criteria, budget ownership, contract value bands and sales cycle analysis across the clinical evaluation, surgeon validation, procurement review and contract award stages.

Competitive benchmarking compares manufacturers across estimated market position, pricing tiers, distribution reach, surgeon training programmes, service infrastructure, regulatory approvals, clinical publications and innovation pipeline.

The market playbook covers pricing and cost structure, the regulatory and compliance environment, customer buying behaviour, clinical adoption trends, distribution channel evolution and technology disruptions.

Pricing and procurement chapters cover product pricing analysis, regional pricing variations, negotiation dynamics, procurement lifecycle analysis and total cost of ownership assessment.

Go-to-market chapters set out market entry pathways, distributor and channel mapping, opinion leader engagement, regulatory approval requirements, reimbursement pathways and major ophthalmology conference activity.

Company profiles cover twelve manufacturers across headquarters, ownership structure, geographic presence, product portfolio, regulatory certifications, strategic partnerships and research and development initiatives.

Frequently Asked Questions

The market is estimated at approximately USD 150 Million in 2025 and is projected to reach approximately USD 215 Million by 2030, expanding at a compound annual growth rate of roughly 7.5 percent. It is segmented across eight dimensions: product type, procedure type, surgical approach, technology platform, end user, glaucoma type, reimbursement environment and procurement model.

No published estimate exists for this device category, so the figure is a disclosed top-down estimate built from the published global glaucoma surgery device market and two analyst assumptions about the share of minimally invasive procedures and the share of microcatheter-based canaloplasty devices within it. The Research Methodology section sets out each step, and the figure should be read as an indicative order of magnitude.

It includes microcatheters used in canaloplasty and related ab-interno and ab-externo procedures, across illuminated, non-illuminated, integrated drug delivery and navigation-enhanced product types. It excludes trabecular micro-bypass stents, drainage implants, topical glaucoma pharmaceuticals and laser trabeculoplasty.

North America accounts for the largest regional concentration, covering the United States and Canada, while Asia-Pacific forms the fastest-growing region, supported by named demand clusters in Australia and Japan and growing surgical capacity across China, India and South Korea.

An ageing population, surgeon preference for combined cataract and canaloplasty procedures, the shift toward ab-interno approaches and MIGS-oriented platforms, product innovation, reimbursement support and growing capacity at ambulatory surgery centres and specialty eye hospitals all support demand.

Adoption is limited by long clinical evaluation and surgeon validation phases, variable reimbursement across countries, vendor selection criteria centred on clinical evidence and regulatory approvals, competitive intensity, distributor-led and tender-based procurement, and the training support buyers expect.

Buyers include ophthalmology hospitals, specialty eye hospitals, ambulatory surgery centres, academic ophthalmology centres and private clinics, purchasing through direct hospital procurement, group purchasing organisations, distributors or integrated surgical packages after a surgeon-led evaluation.

Twelve companies are covered: Nova Eye Medical, iSTAR Medical, Alcon, Glaukos Corporation, New World Medical, Sight Sciences, Johnson & Johnson Vision, Santen Pharmaceutical, Carl Zeiss Meditec, Bausch + Lomb, MicroSurgical Technology and Ellex Medical, grouped by company type rather than ranked.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Glaucoma Surgical Microcatheter Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Rising Global Prevalence of Glaucoma Alongside an Ageing Population, Expanding the Pool of Candidates for Canaloplasty and Other MIGS Procedures That This Report's Glaucoma Type Segmentation Tracks Across Primary Open-Angle, Normal-Tension, Secondary Open-Angle and Pseudoexfoliative Glaucoma.

3.3.2. Growing Surgeon Preference for Combined Cataract and Canaloplasty Procedures, Which the Source's Own Procedure Type Segmentation Identifies as a Distinct and Expanding Category Alongside Standalone and Ab-Interno Canaloplasty.

3.3.3. Continued Shift Toward Ab-Interno Surgical Approaches and MIGS-Oriented Canaloplasty Platforms, Reflecting the Technology Platform Segmentation's Distinction Between Traditional Canaloplasty Systems and Newer Image-Guided Systems.

3.3.4. Expansion of Integrated Drug Delivery and Navigation-Enhanced Microcatheter Categories, Both Named as Distinct Product Type Segments, Widening the Addressable Procedure Base Beyond Conventional Illuminated and Non-Illuminated Designs.

3.3.5. Reimbursement Support Identified as a Named Buying Trigger in the Source, with Public, Mixed and Private Pay Reimbursement Environments All Tracked as Distinct Market Segments Shaping Adoption Pace.

3.3.6. Growth in Ambulatory Surgery Centre and Specialty Eye Hospital Capacity, Both Named End User Categories, Broadening the Sites of Care Where Canaloplasty Procedures Are Performed Outside Traditional Hospital Settings.

3.4. Restraints

3.4.1. Long Clinical Evaluation and Surgeon Validation Phases Before a New Microcatheter Platform Is Adopted, as Reflected in the Source's Own Sales Cycle Analysis (Clinical Evaluation Phase, Surgeon Validation Phase, Procurement Review, Contract Award).

3.4.2. Reimbursement Environment Variability Across Public, Mixed and Private Pay Markets, Which the Source Identifies as a Distinct Segmentation Dimension Shaping Purchasing Willingness by Geography.

3.4.3. Vendor Selection Criteria Centred on Clinical Evidence, Regulatory Approvals and Surgeon Experience, All Named in the Source's Buyer Intelligence Section, Which Raises the Qualification Bar for Newer Entrants Relative to Established Ophthalmic Device Manufacturers.

3.4.4. Competitive Intensity Among Large Diversified Ophthalmology Companies and Focused MIGS Specialists Alike, Spanning the Twelve Companies This Report Covers from Global Majors to Canaloplasty-Focused Specialists.

3.4.5. Distributor-Led and Tender-Based Procurement Models, Both Named Procurement Models in the Source, Which Can Lengthen the Path to Revenue in Markets Outside Direct Manufacturer Contracting.

3.4.6. Training and Surgeon Support Obligations That Vendor Selection Criteria Place on Manufacturers, Given Training Support Is Itself Named as a Distinct Evaluation Criterion in the Source.

3.5. Opportunities

3.5.1. Considerable Untapped Opportunity Identified in the Report's Competitive Mapping and Gaps Across Technology Gaps, Procedure Adoption Gaps and Emerging Market Opportunities.

3.5.2. Regional White Space in Emerging Ophthalmology Markets, a Regional Demand Cluster Named Directly in the Source Alongside Advanced Surgical Markets and Reimbursement-Driven Markets.

3.5.3. Clinical Evidence Gaps Identified in the Report's Own Competitive Mapping and Gaps Section, Favouring Manufacturers That Invest in Clinical Publications and Regulatory Approvals Ahead of Competitors.

3.5.4. Expansion Opportunity Tied to Hybrid MIGS Procedures and Combined Cataract and Canaloplasty Procedures, Both Named Procedure Type Categories That Broaden a Single Microcatheter Platform's Addressable Surgical Volume.

3.5.5. Growth Potential in Group Purchasing Organisation and Integrated Surgical Package Procurement Models, Both Named Procurement Model Categories That Can Accelerate Multi-Hospital Network Adoption.

3.5.6. Geographic Expansion Opportunity Across the State and City Demand Clusters the Source Names Directly, Including Sydney, Melbourne, Brisbane and Perth in Australia, California, Texas, Florida and New York in the United States, Bavaria, North Rhine-Westphalia and Baden-Wurttemberg in Germany, and Tokyo, Osaka and Nagoya in Japan.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Product Type

4.1. Illuminated Canaloplasty Microcatheters

4.2. Non-Illuminated Surgical Microcatheters

4.3. Integrated Drug Delivery Microcatheters

4.4. Next-Generation Navigation-Enhanced Microcatheters

5. Procedure Type

5.1. Canaloplasty

5.2. Ab-Interno Canaloplasty

5.3. Combined Cataract and Canaloplasty Procedures

5.4. Hybrid MIGS Procedures

6. Surgical Approach

6.1. Ab-Interno

6.2. Ab-Externo

7. Technology Platform

7.1. Traditional Canaloplasty Systems

7.2. MIGS-Oriented Canaloplasty Platforms

7.3. Image-Guided Systems

8. End User

8.1. Ophthalmology Hospitals

8.2. Specialty Eye Hospitals

8.3. Ambulatory Surgery Centres

8.4. Academic Ophthalmology Centres

8.5. Private Ophthalmology Clinics

9. Glaucoma Type

9.1. Primary Open-Angle Glaucoma

9.2. Normal-Tension Glaucoma

9.3. Secondary Open-Angle Glaucoma

9.4. Pseudoexfoliative Glaucoma

10. Reimbursement Environment

10.1. Public Reimbursement Markets

10.2. Mixed Reimbursement Markets

10.3. Private Pay Markets

11. Procurement Model

11.1. Direct Hospital Procurement

11.2. Group Purchasing Organisations

11.3. Distributor-Led Procurement

11.4. Integrated Surgical Package Procurement

12. Buyer Intelligence and Demand Landscape

12.1. Buyer Segmentation

12.1.1. Glaucoma Specialists

12.1.2. Cataract Surgeons Performing MIGS

12.1.3. Ophthalmology Hospital Networks

12.1.4. Academic Eye Centres

12.2. Buyer Industry Mapping

12.2.1. Healthcare Providers

12.2.2. Ophthalmology Specialty Care

12.2.3. Academic Medical Institutions

12.3. Buyer Company Types

12.3.1. Public Hospitals

12.3.2. Private Hospital Chains

12.3.3. Specialty Eye Hospitals

12.3.4. Independent Surgical Centres

12.4. Country-Wise Buyer Mapping

12.4.1. North America

12.4.2. Europe

12.4.3. Asia-Pacific

12.4.4. Latin America

12.4.5. Middle East & Africa

12.5. Regional Demand Clusters

12.5.1. Advanced Surgical Markets

12.5.2. Reimbursement-Driven Markets

12.5.3. Emerging Ophthalmology Markets

12.6. Buyer Scale Classification

12.6.1. Large Integrated Hospital Networks

12.6.2. Regional Specialty Providers

12.6.3. Independent Surgical Centres

12.7. Procurement Models

12.7.1. Direct Manufacturer Contracts

12.7.2. Distributor Procurement

12.7.3. Tender-Based Procurement

12.7.4. Group Purchasing Agreements

12.8. Buying Triggers

12.8.1. Clinical Outcome Improvement

12.8.2. Reduced Complication Rates

12.8.3. Reimbursement Support

12.8.4. Procedure Efficiency

12.9. Decision-Maker Roles

12.9.1. Glaucoma Surgeons

12.9.2. Ophthalmology Department Heads

12.9.3. Medical Device Procurement Teams

12.9.4. Hospital Administrators

12.10. Budget Ownership

12.10.1. Ophthalmology Departments

12.10.2. Hospital Capital Equipment Teams

12.10.3. Surgical Services Management

12.11. Vendor Selection Criteria

12.11.1. Clinical Evidence

12.11.2. Regulatory Approvals

12.11.3. Surgeon Experience

12.11.4. Product Reliability

12.11.5. Training Support

12.12. Contract Value Bands

12.12.1. Single-Centre Adoption

12.12.2. Regional Network Agreements

12.12.3. Multi-Hospital Procurement Contracts

12.13. Sales Cycle Analysis

12.13.1. Clinical Evaluation Phase

12.13.2. Surgeon Validation Phase

12.13.3. Procurement Review

12.13.4. Contract Award

12.14. Strategic Relevance for Nova Eye Medical

12.14.1. High-Growth MIGS Adoption Centres

12.14.2. Canaloplasty-Focused Treatment Facilities

12.14.3. Markets with Expanding Glaucoma Surgical Volumes

13. Global Market Analysis and Forecast (2026–2030)

13.1. Introduction

13.2. Market Share Analysis

13.3. Market Size and Forecast

13.4. Market Size and Forecast, By Geography

13.4.1. North America

13.4.1.1. Market Share Analysis

13.4.1.2. Market Size and Forecast

13.4.1.3. By Product

13.4.1.4. By Technology

13.4.1.5. By Application

13.4.1.6. By Customer

13.4.1.7. United States

13.4.1.7.1. Market Share Analysis

13.4.1.7.2. Market Size and Forecast

13.4.1.7.3. By Product

13.4.1.7.4. By Technology

13.4.1.7.5. By Application

13.4.1.7.6. By Customer

13.4.1.7.7. California

13.4.1.7.7.1. Market Share Analysis

13.4.1.7.7.2. Market Size and Forecast

13.4.1.7.7.3. By Product

13.4.1.7.7.4. By Technology

13.4.1.7.7.5. By Application

13.4.1.7.7.6. By Customer

13.4.1.7.8. Texas

13.4.1.7.8.1. Market Share Analysis

13.4.1.7.8.2. Market Size and Forecast

13.4.1.7.8.3. By Product

13.4.1.7.8.4. By Technology

13.4.1.7.8.5. By Application

13.4.1.7.8.6. By Customer

13.4.1.7.9. Florida

13.4.1.7.9.1. Market Share Analysis

13.4.1.7.9.2. Market Size and Forecast

13.4.1.7.9.3. By Product

13.4.1.7.9.4. By Technology

13.4.1.7.9.5. By Application

13.4.1.7.9.6. By Customer

13.4.1.7.10. New York

13.4.1.7.10.1. Market Share Analysis

13.4.1.7.10.2. Market Size and Forecast

13.4.1.7.10.3. By Product

13.4.1.7.10.4. By Technology

13.4.1.7.10.5. By Application

13.4.1.7.10.6. By Customer

13.4.1.8. Canada

13.4.1.8.1. Market Share Analysis

13.4.1.8.2. Market Size and Forecast

13.4.1.8.3. By Product

13.4.1.8.4. By Technology

13.4.1.8.5. By Application

13.4.1.8.6. By Customer

13.4.2. Europe

13.4.2.1. Market Share Analysis

13.4.2.2. Market Size and Forecast

13.4.2.3. By Product

13.4.2.4. By Technology

13.4.2.5. By Application

13.4.2.6. By Customer

13.4.2.7. Germany

13.4.2.7.1. Market Share Analysis

13.4.2.7.2. Market Size and Forecast

13.4.2.7.3. By Product

13.4.2.7.4. By Technology

13.4.2.7.5. By Application

13.4.2.7.6. By Customer

13.4.2.7.7. Bavaria

13.4.2.7.7.1. Market Share Analysis

13.4.2.7.7.2. Market Size and Forecast

13.4.2.7.7.3. By Product

13.4.2.7.7.4. By Technology

13.4.2.7.7.5. By Application

13.4.2.7.7.6. By Customer

13.4.2.7.8. North Rhine-Westphalia

13.4.2.7.8.1. Market Share Analysis

13.4.2.7.8.2. Market Size and Forecast

13.4.2.7.8.3. By Product

13.4.2.7.8.4. By Technology

13.4.2.7.8.5. By Application

13.4.2.7.8.6. By Customer

13.4.2.7.9. Baden-Wurttemberg

13.4.2.7.9.1. Market Share Analysis

13.4.2.7.9.2. Market Size and Forecast

13.4.2.7.9.3. By Product

13.4.2.7.9.4. By Technology

13.4.2.7.9.5. By Application

13.4.2.7.9.6. By Customer

13.4.2.8. United Kingdom

13.4.2.8.1. Market Share Analysis

13.4.2.8.2. Market Size and Forecast

13.4.2.8.3. By Product

13.4.2.8.4. By Technology

13.4.2.8.5. By Application

13.4.2.8.6. By Customer

13.4.2.9. France

13.4.2.9.1. Market Share Analysis

13.4.2.9.2. Market Size and Forecast

13.4.2.9.3. By Product

13.4.2.9.4. By Technology

13.4.2.9.5. By Application

13.4.2.9.6. By Customer

13.4.2.10. Italy

13.4.2.10.1. Market Share Analysis

13.4.2.10.2. Market Size and Forecast

13.4.2.10.3. By Product

13.4.2.10.4. By Technology

13.4.2.10.5. By Application

13.4.2.10.6. By Customer

13.4.2.11. Spain

13.4.2.11.1. Market Share Analysis

13.4.2.11.2. Market Size and Forecast

13.4.2.11.3. By Product

13.4.2.11.4. By Technology

13.4.2.11.5. By Application

13.4.2.11.6. By Customer

13.4.2.12. Netherlands

13.4.2.12.1. Market Share Analysis

13.4.2.12.2. Market Size and Forecast

13.4.2.12.3. By Product

13.4.2.12.4. By Technology

13.4.2.12.5. By Application

13.4.2.12.6. By Customer

13.4.3. Asia-Pacific

13.4.3.1. Market Share Analysis

13.4.3.2. Market Size and Forecast

13.4.3.3. By Product

13.4.3.4. By Technology

13.4.3.5. By Application

13.4.3.6. By Customer

13.4.3.7. Australia

13.4.3.7.1. Market Share Analysis

13.4.3.7.2. Market Size and Forecast

13.4.3.7.3. By Product

13.4.3.7.4. By Technology

13.4.3.7.5. By Application

13.4.3.7.6. By Customer

13.4.3.7.7. Sydney

13.4.3.7.7.1. Market Share Analysis

13.4.3.7.7.2. Market Size and Forecast

13.4.3.7.7.3. By Product

13.4.3.7.7.4. By Technology

13.4.3.7.7.5. By Application

13.4.3.7.7.6. By Customer

13.4.3.7.8. Melbourne

13.4.3.7.8.1. Market Share Analysis

13.4.3.7.8.2. Market Size and Forecast

13.4.3.7.8.3. By Product

13.4.3.7.8.4. By Technology

13.4.3.7.8.5. By Application

13.4.3.7.8.6. By Customer

13.4.3.7.9. Brisbane

13.4.3.7.9.1. Market Share Analysis

13.4.3.7.9.2. Market Size and Forecast

13.4.3.7.9.3. By Product

13.4.3.7.9.4. By Technology

13.4.3.7.9.5. By Application

13.4.3.7.9.6. By Customer

13.4.3.7.10. Perth

13.4.3.7.10.1. Market Share Analysis

13.4.3.7.10.2. Market Size and Forecast

13.4.3.7.10.3. By Product

13.4.3.7.10.4. By Technology

13.4.3.7.10.5. By Application

13.4.3.7.10.6. By Customer

13.4.3.8. Japan

13.4.3.8.1. Market Share Analysis

13.4.3.8.2. Market Size and Forecast

13.4.3.8.3. By Product

13.4.3.8.4. By Technology

13.4.3.8.5. By Application

13.4.3.8.6. By Customer

13.4.3.8.7. Tokyo

13.4.3.8.7.1. Market Share Analysis

13.4.3.8.7.2. Market Size and Forecast

13.4.3.8.7.3. By Product

13.4.3.8.7.4. By Technology

13.4.3.8.7.5. By Application

13.4.3.8.7.6. By Customer

13.4.3.8.8. Osaka

13.4.3.8.8.1. Market Share Analysis

13.4.3.8.8.2. Market Size and Forecast

13.4.3.8.8.3. By Product

13.4.3.8.8.4. By Technology

13.4.3.8.8.5. By Application

13.4.3.8.8.6. By Customer

13.4.3.8.9. Nagoya

13.4.3.8.9.1. Market Share Analysis

13.4.3.8.9.2. Market Size and Forecast

13.4.3.8.9.3. By Product

13.4.3.8.9.4. By Technology

13.4.3.8.9.5. By Application

13.4.3.8.9.6. By Customer

13.4.3.9. China

13.4.3.9.1. Market Share Analysis

13.4.3.9.2. Market Size and Forecast

13.4.3.9.3. By Product

13.4.3.9.4. By Technology

13.4.3.9.5. By Application

13.4.3.9.6. By Customer

13.4.3.10. South Korea

13.4.3.10.1. Market Share Analysis

13.4.3.10.2. Market Size and Forecast

13.4.3.10.3. By Product

13.4.3.10.4. By Technology

13.4.3.10.5. By Application

13.4.3.10.6. By Customer

13.4.3.11. India

13.4.3.11.1. Market Share Analysis

13.4.3.11.2. Market Size and Forecast

13.4.3.11.3. By Product

13.4.3.11.4. By Technology

13.4.3.11.5. By Application

13.4.3.11.6. By Customer

13.4.3.12. Singapore

13.4.3.12.1. Market Share Analysis

13.4.3.12.2. Market Size and Forecast

13.4.3.12.3. By Product

13.4.3.12.4. By Technology

13.4.3.12.5. By Application

13.4.3.12.6. By Customer

13.4.4. Latin America

13.4.4.1. Market Share Analysis

13.4.4.2. Market Size and Forecast

13.4.4.3. By Product

13.4.4.4. By Technology

13.4.4.5. By Application

13.4.4.6. By Customer

13.4.4.7. Brazil

13.4.4.7.1. Market Share Analysis

13.4.4.7.2. Market Size and Forecast

13.4.4.7.3. By Product

13.4.4.7.4. By Technology

13.4.4.7.5. By Application

13.4.4.7.6. By Customer

13.4.4.8. Mexico

13.4.4.8.1. Market Share Analysis

13.4.4.8.2. Market Size and Forecast

13.4.4.8.3. By Product

13.4.4.8.4. By Technology

13.4.4.8.5. By Application

13.4.4.8.6. By Customer

13.4.5. Middle East & Africa

13.4.5.1. Market Share Analysis

13.4.5.2. Market Size and Forecast

13.4.5.3. By Product

13.4.5.4. By Technology

13.4.5.5. By Application

13.4.5.6. By Customer

13.4.5.7. Saudi Arabia

13.4.5.7.1. Market Share Analysis

13.4.5.7.2. Market Size and Forecast

13.4.5.7.3. By Product

13.4.5.7.4. By Technology

13.4.5.7.5. By Application

13.4.5.7.6. By Customer

13.4.5.8. United Arab Emirates

13.4.5.8.1. Market Share Analysis

13.4.5.8.2. Market Size and Forecast

13.4.5.8.3. By Product

13.4.5.8.4. By Technology

13.4.5.8.5. By Application

13.4.5.8.6. By Customer

13.4.5.9. South Africa

13.4.5.9.1. Market Share Analysis

13.4.5.9.2. Market Size and Forecast

13.4.5.9.3. By Product

13.4.5.9.4. By Technology

13.4.5.9.5. By Application

13.4.5.9.6. By Customer

14. Competition Analysis

14.1. Market Positioning Overview

14.1.1. Global and Regional Positioning

14.1.2. Pricing and Value Proposition Analysis

14.1.3. Technology Leadership Assessment

14.1.4. Clinical Evidence Benchmarking

14.1.5. Procedure Adoption Positioning

14.2. Competitive Benchmarking Metrics

14.2.1. Estimated Market Position

14.2.2. Pricing Tiers

14.2.3. Distribution Reach

14.2.4. Surgeon Training Programmes

14.2.5. Service Infrastructure

14.2.6. Regulatory Approvals

14.2.7. Clinical Publications

14.2.8. Innovation Pipeline

14.3. Strategic Moves

14.3.1. Product Launches

14.3.2. Technology Partnerships

14.3.3. Distribution Agreements

14.3.4. Geographic Expansion

14.3.5. Clinical Trial Initiatives

14.3.6. Regulatory Milestones

14.4. Competitive Mapping & Gaps

14.4.1. Technology Gaps

14.4.2. Procedure Adoption Gaps

14.4.3. Considerable Untapped Regional Opportunity

14.4.4. Emerging Market Opportunities

14.4.5. Clinical Evidence Gaps

15. Company Profiles

15.1. Nova Eye Medical

15.1.1. Corporate Overview

15.1.2. Headquarters

15.1.3. Ownership Structure

15.1.4. Founding Year

15.1.5. Workforce Estimate

15.1.6. Geographic Presence

15.1.7. Product Portfolio

15.1.8. Glaucoma Surgical Portfolio

15.1.9. Target Customer Segments

15.1.10. Distribution Strategy

15.1.11. Revenue Indicators

15.1.12. Regulatory Certifications

15.1.13. Strategic Partnerships

15.1.14. R&D Initiatives

15.1.15. Recent Developments

15.1.16. SWOT Analysis

15.2. iSTAR Medical

15.2.1. Corporate Overview

15.2.2. Headquarters

15.2.3. Ownership Structure

15.2.4. Founding Year

15.2.5. Workforce Estimate

15.2.6. Geographic Presence

15.2.7. Product Portfolio

15.2.8. Glaucoma Surgical Portfolio

15.2.9. Target Customer Segments

15.2.10. Distribution Strategy

15.2.11. Revenue Indicators

15.2.12. Regulatory Certifications

15.2.13. Strategic Partnerships

15.2.14. R&D Initiatives

15.2.15. Recent Developments

15.2.16. SWOT Analysis

15.3. Alcon

15.3.1. Corporate Overview

15.3.2. Headquarters

15.3.3. Ownership Structure

15.3.4. Founding Year

15.3.5. Workforce Estimate

15.3.6. Geographic Presence

15.3.7. Product Portfolio

15.3.8. Glaucoma Surgical Portfolio

15.3.9. Target Customer Segments

15.3.10. Distribution Strategy

15.3.11. Revenue Indicators

15.3.12. Regulatory Certifications

15.3.13. Strategic Partnerships

15.3.14. R&D Initiatives

15.3.15. Recent Developments

15.3.16. SWOT Analysis

15.4. Glaukos Corporation

15.4.1. Corporate Overview

15.4.2. Headquarters

15.4.3. Ownership Structure

15.4.4. Founding Year

15.4.5. Workforce Estimate

15.4.6. Geographic Presence

15.4.7. Product Portfolio

15.4.8. Glaucoma Surgical Portfolio

15.4.9. Target Customer Segments

15.4.10. Distribution Strategy

15.4.11. Revenue Indicators

15.4.12. Regulatory Certifications

15.4.13. Strategic Partnerships

15.4.14. R&D Initiatives

15.4.15. Recent Developments

15.4.16. SWOT Analysis

15.5. New World Medical

15.5.1. Corporate Overview

15.5.2. Headquarters

15.5.3. Ownership Structure

15.5.4. Founding Year

15.5.5. Workforce Estimate

15.5.6. Geographic Presence

15.5.7. Product Portfolio

15.5.8. Glaucoma Surgical Portfolio

15.5.9. Target Customer Segments

15.5.10. Distribution Strategy

15.5.11. Revenue Indicators

15.5.12. Regulatory Certifications

15.5.13. Strategic Partnerships

15.5.14. R&D Initiatives

15.5.15. Recent Developments

15.5.16. SWOT Analysis

15.6. Sight Sciences

15.6.1. Corporate Overview

15.6.2. Headquarters

15.6.3. Ownership Structure

15.6.4. Founding Year

15.6.5. Workforce Estimate

15.6.6. Geographic Presence

15.6.7. Product Portfolio

15.6.8. Glaucoma Surgical Portfolio

15.6.9. Target Customer Segments

15.6.10. Distribution Strategy

15.6.11. Revenue Indicators

15.6.12. Regulatory Certifications

15.6.13. Strategic Partnerships

15.6.14. R&D Initiatives

15.6.15. Recent Developments

15.6.16. SWOT Analysis

15.7. Johnson & Johnson Vision

15.7.1. Corporate Overview

15.7.2. Headquarters

15.7.3. Ownership Structure

15.7.4. Founding Year

15.7.5. Workforce Estimate

15.7.6. Geographic Presence

15.7.7. Product Portfolio

15.7.8. Glaucoma Surgical Portfolio

15.7.9. Target Customer Segments

15.7.10. Distribution Strategy

15.7.11. Revenue Indicators

15.7.12. Regulatory Certifications

15.7.13. Strategic Partnerships

15.7.14. R&D Initiatives

15.7.15. Recent Developments

15.7.16. SWOT Analysis

15.8. Santen Pharmaceutical

15.8.1. Corporate Overview

15.8.2. Headquarters

15.8.3. Ownership Structure

15.8.4. Founding Year

15.8.5. Workforce Estimate

15.8.6. Geographic Presence

15.8.7. Product Portfolio

15.8.8. Glaucoma Surgical Portfolio

15.8.9. Target Customer Segments

15.8.10. Distribution Strategy

15.8.11. Revenue Indicators

15.8.12. Regulatory Certifications

15.8.13. Strategic Partnerships

15.8.14. R&D Initiatives

15.8.15. Recent Developments

15.8.16. SWOT Analysis

15.9. Carl Zeiss Meditec

15.9.1. Corporate Overview

15.9.2. Headquarters

15.9.3. Ownership Structure

15.9.4. Founding Year

15.9.5. Workforce Estimate

15.9.6. Geographic Presence

15.9.7. Product Portfolio

15.9.8. Glaucoma Surgical Portfolio

15.9.9. Target Customer Segments

15.9.10. Distribution Strategy

15.9.11. Revenue Indicators

15.9.12. Regulatory Certifications

15.9.13. Strategic Partnerships

15.9.14. R&D Initiatives

15.9.15. Recent Developments

15.9.16. SWOT Analysis

15.10. Bausch + Lomb

15.10.1. Corporate Overview

15.10.2. Headquarters

15.10.3. Ownership Structure

15.10.4. Founding Year

15.10.5. Workforce Estimate

15.10.6. Geographic Presence

15.10.7. Product Portfolio

15.10.8. Glaucoma Surgical Portfolio

15.10.9. Target Customer Segments

15.10.10. Distribution Strategy

15.10.11. Revenue Indicators

15.10.12. Regulatory Certifications

15.10.13. Strategic Partnerships

15.10.14. R&D Initiatives

15.10.15. Recent Developments

15.10.16. SWOT Analysis

15.11. MicroSurgical Technology

15.11.1. Corporate Overview

15.11.2. Headquarters

15.11.3. Ownership Structure

15.11.4. Founding Year

15.11.5. Workforce Estimate

15.11.6. Geographic Presence

15.11.7. Product Portfolio

15.11.8. Glaucoma Surgical Portfolio

15.11.9. Target Customer Segments

15.11.10. Distribution Strategy

15.11.11. Revenue Indicators

15.11.12. Regulatory Certifications

15.11.13. Strategic Partnerships

15.11.14. R&D Initiatives

15.11.15. Recent Developments

15.11.16. SWOT Analysis

15.12. Ellex Medical

15.12.1. Corporate Overview

15.12.2. Headquarters

15.12.3. Ownership Structure

15.12.4. Founding Year

15.12.5. Workforce Estimate

15.12.6. Geographic Presence

15.12.7. Product Portfolio

15.12.8. Glaucoma Surgical Portfolio

15.12.9. Target Customer Segments

15.12.10. Distribution Strategy

15.12.11. Revenue Indicators

15.12.12. Regulatory Certifications

15.12.13. Strategic Partnerships

15.12.14. R&D Initiatives

15.12.15. Recent Developments

15.12.16. SWOT Analysis

Frequently Asked Questions

The market is estimated at approximately USD 150 Million in 2025 and is projected to reach approximately USD 215 Million by 2030, expanding at a compound annual growth rate of roughly 7.5 percent. It is segmented across eight dimensions: product type, procedure type, surgical approach, technology platform, end user, glaucoma type, reimbursement environment and procurement model.

No published estimate exists for this device category, so the figure is a disclosed top-down estimate built from the published global glaucoma surgery device market and two analyst assumptions about the share of minimally invasive procedures and the share of microcatheter-based canaloplasty devices within it. The Research Methodology section sets out each step, and the figure should be read as an indicative order of magnitude.

It includes microcatheters used in canaloplasty and related ab-interno and ab-externo procedures, across illuminated, non-illuminated, integrated drug delivery and navigation-enhanced product types. It excludes trabecular micro-bypass stents, drainage implants, topical glaucoma pharmaceuticals and laser trabeculoplasty.

North America accounts for the largest regional concentration, covering the United States and Canada, while Asia-Pacific forms the fastest-growing region, supported by named demand clusters in Australia and Japan and growing surgical capacity across China, India and South Korea.

An ageing population, surgeon preference for combined cataract and canaloplasty procedures, the shift toward ab-interno approaches and MIGS-oriented platforms, product innovation, reimbursement support and growing capacity at ambulatory surgery centres and specialty eye hospitals all support demand.

Adoption is limited by long clinical evaluation and surgeon validation phases, variable reimbursement across countries, vendor selection criteria centred on clinical evidence and regulatory approvals, competitive intensity, distributor-led and tender-based procurement, and the training support buyers expect.

Buyers include ophthalmology hospitals, specialty eye hospitals, ambulatory surgery centres, academic ophthalmology centres and private clinics, purchasing through direct hospital procurement, group purchasing organisations, distributors or integrated surgical packages after a surgeon-led evaluation.

Twelve companies are covered: Nova Eye Medical, iSTAR Medical, Alcon, Glaukos Corporation, New World Medical, Sight Sciences, Johnson & Johnson Vision, Santen Pharmaceutical, Carl Zeiss Meditec, Bausch + Lomb, MicroSurgical Technology and Ellex Medical, grouped by company type rather than ranked.

Inquire Before Buying Request Free Sample Ask For Discount

Glaucoma surgical microcatheters separated from the wider glaucoma surgery device market

Glaucoma surgical microcatheters are reported inside the much larger glaucoma surgery device market, which spans drainage implants, trabecular micro-bypass stents, cutting and ablation devices and other minimally invasive and conventional surgical products not comparable with the activity described here. This estimate covers microcatheters used in canaloplasty-type glaucoma procedures only. The snapshot table states that boundary so the figure is not mistaken for anything larger.

Disclosed top-down derivation in the absence of a published niche estimate

No published market estimate for glaucoma surgical microcatheters, globally or by region, was found during research, so this figure is a top-down estimate rather than a sourced one. It starts from an independently published 2025 global glaucoma surgery devices market estimate of approximately USD 1.86 Billion, cross-checked against a second independent estimate of approximately USD 1.9 Billion for 2026. It then applies two analyst assumptions that are not drawn from any external source, namely that minimally invasive glaucoma surgery devices represent roughly 30 percent of glaucoma surgery device revenue and that microcatheter-based canaloplasty devices represent roughly 27 percent of that minimally invasive total. The result is a base of approximately USD 150 Million for 2025.

Growth rate cross-checked against adjacent published estimates

Published growth rates for the wider market sit at approximately 4.6 percent a year for glaucoma surgery devices as a whole and at approximately 5.4 to 5.5 percent a year for the minimally invasive glaucoma surgery segment, with the faster segment growth in both sources. A working rate of roughly 7.5 percent was adopted for this narrower device category, which adds about two percentage points to the minimally invasive segment rate to reflect adoption of combined cataract and canaloplasty procedures and newer platforms. That uplift is also an analyst assumption, and it carries the 2025 base to approximately USD 215 Million in 2030.

Forecast basis, confidence and principal sensitivity

The forecast assumes glaucoma surgical volumes continue to grow broadly in line with recent trends and that reimbursement for minimally invasive glaucoma procedures remains broadly stable. Because the two share assumptions and the growth uplift are unsourced, the stated figures should be treated as indicative estimates with a wide margin of uncertainty, since a minimally invasive share of 20 percent or 40 percent instead of 30 percent would move the base to roughly USD 100 Million or USD 200 Million respectively. Reimbursement coverage for minimally invasive glaucoma procedures and surgeon adoption of combined procedures are the material sensitivities.

Frequently Asked Questions

The market is estimated at approximately USD 150 Million in 2025 and is projected to reach approximately USD 215 Million by 2030, expanding at a compound annual growth rate of roughly 7.5 percent. It is segmented across eight dimensions: product type, procedure type, surgical approach, technology platform, end user, glaucoma type, reimbursement environment and procurement model.

No published estimate exists for this device category, so the figure is a disclosed top-down estimate built from the published global glaucoma surgery device market and two analyst assumptions about the share of minimally invasive procedures and the share of microcatheter-based canaloplasty devices within it. The Research Methodology section sets out each step, and the figure should be read as an indicative order of magnitude.

It includes microcatheters used in canaloplasty and related ab-interno and ab-externo procedures, across illuminated, non-illuminated, integrated drug delivery and navigation-enhanced product types. It excludes trabecular micro-bypass stents, drainage implants, topical glaucoma pharmaceuticals and laser trabeculoplasty.

North America accounts for the largest regional concentration, covering the United States and Canada, while Asia-Pacific forms the fastest-growing region, supported by named demand clusters in Australia and Japan and growing surgical capacity across China, India and South Korea.

An ageing population, surgeon preference for combined cataract and canaloplasty procedures, the shift toward ab-interno approaches and MIGS-oriented platforms, product innovation, reimbursement support and growing capacity at ambulatory surgery centres and specialty eye hospitals all support demand.

Adoption is limited by long clinical evaluation and surgeon validation phases, variable reimbursement across countries, vendor selection criteria centred on clinical evidence and regulatory approvals, competitive intensity, distributor-led and tender-based procurement, and the training support buyers expect.

Buyers include ophthalmology hospitals, specialty eye hospitals, ambulatory surgery centres, academic ophthalmology centres and private clinics, purchasing through direct hospital procurement, group purchasing organisations, distributors or integrated surgical packages after a surgeon-led evaluation.

Twelve companies are covered: Nova Eye Medical, iSTAR Medical, Alcon, Glaukos Corporation, New World Medical, Sight Sciences, Johnson & Johnson Vision, Santen Pharmaceutical, Carl Zeiss Meditec, Bausch + Lomb, MicroSurgical Technology and Ellex Medical, grouped by company type rather than ranked.

Inquire Before Buying Request Free Sample Ask For Discount